Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?

Bibliographical data

Original languageEnglish
ISSN0007-0963
DOIs
Publication statusPublished - 10.2022
PubMed 35442535